Bio-Techne Releases Second Quarter Fiscal 2026 Results

About this update from Bio-techne Corp

[{"type":"text","content":"MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025.","length":165,"tagName":"p"},{"type":"text","content":"Second Quarter FY2026 Highlights","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive quarter.","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":510,"olType":false},{"type":"text","content":""I am pleased with the Bio-Techne team's continued execution in a stabilizing operating environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma. That momentum, together with improving performance in biotech, continued stabilization among our U.S. academic customers, and ongoing growth in Asia, drove results that were largely in line with our expectations."","length":522,"tagName":"p"},{"type":"text","content":"Kelderman continued, "In 2026, Bio-Techne proudly celebrates its 50th anniversary. Over the past five decades, we have built a durable, differentiated portfolio that serves high-growth, high-value applications and accelerates innovation in science and medicine. I am incredibly proud of what we have accomplished to date. As we look ahead, our strong position enables us to drive continued innovation, growth, and value for all our stakeholders."","length":456,"tagName":"p"},{"type":"text","content":"Conference Call","length":15,"tagName":"p"},{"type":"text","content":"Bio-Techne will host an earnings confere...

More updates from Bio-techne Corp